Question 1

Which countries lead Lung Cancer Research Studies research?

Accepted Answer

By volume, China and the United States publish the most (3.1k and 2.5k works in 2022-now).

Question 2

Which institutions lead Lung Cancer Research Studies research?

Accepted Answer

By volume in 2022-now, Sun Yat-sen University publishes the most Lung Cancer Research Studies research, followed by Chinese Academy of Medical Sciences & Peking Union Medical College and Harvard University.

Question 3

Who are the leading researchers in Lung Cancer Research Studies?

Accepted Answer

The most-cited researchers publishing on Lung Cancer Research Studies include Ahmedin Jemal, Stacey L. Gabriel and Julian P. T. Higgins.

Question 4

Where is Lung Cancer Research Studies research done?

Accepted Answer

The largest centres of Lung Cancer Research Studies research in 2022-now are Beijing (China), Shanghai (China), Guangzhou (China) and New York (United States). Among places with at least 20 works in it, it is an unusually large share of all research in Plainview and Kashiwa.

Question 5

Where is the best place to study Lung Cancer Research Studies?

Accepted Answer

Among universities, judged by research, Harvard University, Cornell University and Sun Yat-sen University score highest, combining citation excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

Question 6

Is Lung Cancer Research Studies research growing?

Accepted Answer

Output in 2022-2025 was 19% higher than in 2018-2021, peaking in 2025. The fastest-growing topics are Lung Cancer Research Studies.

Question 7

What are the most cited papers in Lung Cancer Research Studies?

Accepted Answer

The most cited paper in Lung Cancer Research Studies is "Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer" (Julie Renee Brahmer et al., 2015), with 8,632 citations. Next come "Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma" (8,331) and "Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial" (5,563).